过氧化物酶体增殖物激活受体γ激动剂吡格列酮改善系统性红斑狼疮的血管与代谢功能障碍
这项双盲交叉设计随机对照试验纳入80例轻至重度活动性系统性红斑狼疮(SLE)患者,比较吡格列酮(PGZ)与安慰剂序贯治疗各3个月(洗脱期2个月)的效果。72例完成研究,PGZ较安慰剂显著降低心踝血管指数(动脉僵硬度指标),并改善胰岛素抵抗、脂蛋白谱及循环中性粒细胞胞外诱捕网水平。PGZ耐受性良好,多数不良事件轻微且减量后缓解。
要点
- PGZ较安慰剂显著降低SLE患者心踝血管指数,改善动脉僵硬度。
- PGZ改善胰岛素抵抗和脂蛋白谱等代谢参数。
- PGZ较安慰剂显著降低循环中性粒细胞胞外诱捕网水平。
核心结论
- PGZ耐受性良好,并显著改善SLE患者的血管僵硬度及心血管代谢参数。
- 结果提示PGZ应作为SLE心血管疾病风险调节剂进一步探索。
研究设计与样本
- 双盲交叉设计随机对照试验,80例轻至重度疾病活动度的SLE受试者随机接受PGZ后安慰剂序贯治疗各3个月或相反顺序,洗脱期2个月。
主要发现
- 72例受试者完成研究。
- PGZ较安慰剂显著降低心踝血管指数(动脉僵硬度指标)。
- PGZ较安慰剂改善胰岛素抵抗和脂蛋白谱等多种代谢参数。
- PGZ较安慰剂显著降低循环中性粒细胞胞外诱捕网水平。
- PGZ治疗期间多数不良事件为轻度,减量后缓解。
关键数值与推荐
- 主要终点为通过多模式评估测量的内皮功能和动脉炎症参数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Premature cardiovascular events in systemic lupus erythematosus (SLE) contribute to morbidity and mortality, with no effective preventive strategies described to date. Immune dysregulation and metabolic disturbances appear to play prominent roles in the induction of vascular disease in SLE. The peroxisome proliferator activated receptor-gamma agonist pioglitazone (PGZ suppresses vascular damage and immune dysregulation in murine lupus and improves endothelial dysfunction in other inflammatory diseases. We hypothesised that PGZ could improve vascular dysfunction and cardiometabolic parameters in SLE. METHODS: Eighty SLE subjects with mild to severe disease activity were randomised to a sequence of PGZ followed by placebo for 3 months, or vice versa, in a double-blind, cross-over design with a 2-month wash-out period. Primary endpoints were parameters of endothelial function and arterial inflammation, measured by multimodal assessments. Additional outcome measures of disease activity, neutrophil dysregulation, metabolic disturbances and gene expression studies were performed. RESULTS: Seventy-two subjects completed the study. PGZ was associated with a significant reduction in Cardio-Ankle Vascular Index (a measure of arterial stiffness) compared with placebo. Various metabolic parameters improved with PGZ, including insulin resistance and lipoprotein profiles. Circulating neutrophil extracellular trap levels also significantly decreased with PGZ compared with placebo. Most adverse events experienced while on PGZ were mild and resolved with reduction in PGZ dose. CONCLUSION: PGZ was well tolerated and induced significant improvement in vascular stiffness and cardiometabolic parameters in SLE. The results suggest that PGZ should be further explored as a modulator of cardiovascular disease risk in SLE. TRIAL REGISTRATION NUMBER: NCT02338999.
引用
- Hasni S, Temesgen-Oyelakin Y, Davis M, et al. Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus. Ann Rheum Dis. 2022. PMID: 35914929. doi:10.1136/ard-2022-222658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。